Search the GHTC website

Global health R&D delivers for Kansas

US government investment in global health R&D has delivered

$79.6 million
to Kansas research institutions
900+ new jobs
for Kansas
Kansas's top USG-funded global health R&D institutions

Kansas's top USG-funded global health R&D institutions

University of Kansas
$36.4 million
Kansas State University
$24.7 million
Children's Mercy Hospital Kansas
$6.5 million
University of Kansas Medical Center
$5.3 million
ViroVax LLC
$3.7 million
Acenxion Biosystems
$2 million
Oak Therapeutics Inc.
$486 thousand
Impedx Diagnostics Inc.*
$346 thousand
Foothold Labs Inc.
$160 thousand
Leading Edge PharmTox LLC
$36 thousand

Kansas's top areas of global health R&D by USG funding

Other coronaviruses (including MERS, SARS)
Diarrheal diseases
Neglected tropical diseases
Kinetoplastid diseases
Reproductive health
Salmonella infections
Bunyaviral diseases (including CCHF, RVF, SFTS)
Cryptococcal meningitis
Multi-disease/health area R&D
Global health R&D at work in Kansas

Researchers at the University of Kansas (KU) are working to reformulate vaccines to make them more suitable for delivery in the world’s poorest places. The team explores ways to tweak the formulations of vaccines to reduce manufacturing and material costs, extend their shelf life, eliminate the need for refrigeration, enable oral or needle-free delivery, or even allow them to be combined with other vaccines into multi-disease fighting shots. Their goal is to produce vaccines that are less expensive to manufacture and more capable of surviving harsh conditions along the “last mile” journey to reach patients. Affordable and reliable vaccines are a crucial element of disease prevention programs around the world. Delivered effectively, they can save lives and improve the health of entire populations.

  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: PATH/Gabe Bienczycki